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Abstract
 
Members of the genus
 
 Trypanosoma
 
 cause African trypanosomiasis in humans and animals in
Africa. Infection of mammals by African trypanosomes is characterized by an upregulation of
prostaglandin (PG) production in the plasma and cerebrospinal fluid. These metabolites of
arachidonic acid (AA) may, in part, be responsible for symptoms such as fever, headache, im-
munosuppression, deep muscle hyperaesthesia, miscarriage, ovarian dysfunction, sleepiness, and
other symptoms observed in patients with chronic African trypanosomiasis. Here, we show that
the protozoan parasite 
 
T. brucei
 
 is involved in PG production and that it produces PGs enzy-
matically from AA and its metabolite, PGH
 
2
 
. Among all PGs synthesized, PGF
 
2
 
a
 
 was the major
prostanoid produced by trypanosome lysates. We have purified a novel 
 
T. brucei
 
 PGF
 
2
 
a
 
 syn-
thase (TbPGFS) and cloned its cDNA. Phylogenetic analysis and molecular properties revealed
that TbPGFS is completely distinct from mammalian PGF synthases. We also found that Tb-
PGFS mRNA expression and TbPGFS activity were high in the early logarithmic growth
phase and low during the stationary phase. The characterization of TbPGFS and its gene in 
 
T.
brucei
 
 provides a basis for the molecular analysis of the role of parasite-derived PGF
 
2
 
a
 
 in the
physiology of the parasite and the pathogenesis of African trypanosomiasis.
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Introduction
 
Prostaglandins (PGs)
 
1
 
 of the 2 series are synthesized by the
oxygenation of AA. In this pathway, AA is converted to
PGH
 
2
 
 by cyclooxygenases (COX-1 and -2). Subsequently,
the resulting PGH
 
2
 
 is converted in vivo and in vitro to
various arachidonate metabolites, such as PGD
 
2
 
, PGE
 
2
 
,
 
and PGF
 
2
 
a 
 
(Fig. 1) by the action of their respective syn-
thases (1).
PGs are actively produced and widely distributed in var-
ious tissues of mammals, where they are potent mediators
of a large variety of physiological and pathological re-
sponses including regulation of vascular tone, miscarriage,
ovarian dysfunction, infertility, sleepiness, inflammation,
bronchoconstriction, pain, fever, immunosuppression, and
other symptoms (2–7). However, PG production is not re-
stricted to mammals. Studies have shown the production of
PGs by parasites such as cestodes, trematodes, nematodes,
and protozoa (8–13) in response to the addition of AA or
calcium ionophore. In 
 
Schistosoma mansoni
 
, PG production
has been reported to be associated with the transformation
of cercaria into schistosomules (14), whereas in the proto-
zoan parasite 
 
Amoeba proteus
 
, PGs may play a signal-cou-
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pling role during phagocytosis, because they elicit vacuole
formation (15). PGF
 
2
 
a
 
 and PGD
 
2
 
 are also found to be con-
sistently elevated in the plasma
 
 
 
of animals experimentally
infected with 
 
Trypanosoma congolense
 
 (16) and in the cere-
brospinal fluid of humans with chronic infection of 
 
T. bru-
cei gambiense
 
 (17), respectively. These results suggest an
upregulation of PG production during African trypanoso-
miasis. However, the molecular basis for this upregulation
has not yet been elucidated. In addition, despite the obvi-
ous importance of PGs in the pathogenesis of parasitic in-
fections and of PG production in parasitic protozoa, little is
known about the molecular mechanisms of PG production
in these organisms. The results presented here identify for
the first time a 
 
T. brucei
 
 protein that exhibits a PGF syn-
thase activity capable of specifically converting PGH
 
2
 
 to
PGF
 
2
 
a
 
.
 
Materials and Methods
 
Nucleotide Sequence Data.
 
The nucleotide sequence data re-
ported in this paper is available from EMBL/GenBank/DDBJ
under accession number AB034727.
 
T. brucei Cells.
 
Bloodstream forms of 
 
T. brucei
 
 clone MITat
1.4 were isolated from infected rats as described previously (18).
Trypanosome cells were cultivated in the presence or absence of
66 
 
m
 
M AA in a modified minimum essential medium supple-
mented with 10% FCS. The culture was incubated in a 5% CO
 
2
 
atmosphere at 37
 
8
 
C as described previously (18–20). Cells were
harvested from the logarithmic growth phase or from the late sta-
tionary phase by centrifugation (1,500 
 
g
 
) at 4
 
8
 
C for 5 min. Cells
were lysed and used as enzyme sources. After centrifugation, the
supernatants were used for the determination of PGs secreted
into the culture medium by live trypanosomes.
 
Incubation of T. brucei Lysates and Enzyme Assay.
 
Lysates from
logarithmic growth phase 
 
T. brucei
 
 (2.5 
 
3 
 
10
 
8
 
 cells) isolated from
infected rats and from the logarithmic growth and late stationary
phase (8.3 and 5.4 
 
3
 
 10
 
7
 
 cells, respectively) organisms isolated
 
from bloodstream-form cultures were prepared by hypotonic lysis
using double-distilled water containing a cocktail of reversible
and irreversible inhibitors (one tablet in 25 ml) of pancreas ex-
tract, pronase, thermolysin, chemotrypsin, trypsin, and papain
(Complete™; Roche Diagnostics). For PG production from AA,
we used the reaction mixture described by Ujihara et al. (21) with
the following modifications: 100 mM sodium phosphate, pH 7.0,
2 
 
m
 
M hematin, 5 mM tryptophan, 1 mM AA, and 300 
 
m
 
l of the
respective 
 
T. brucei
 
 lysates in a final volume of 500 
 
m
 
l. The mix-
ture was incubated at 37
 
8
 
C for 30 min, and then the reaction was
stopped by addition of 100 
 
m
 
l of 1 M HCl and 6 vol of cold ethyl
acetate.
For PGF
 
2
 
a
 
 synthesis from PGH
 
2
 
, a standard reaction mixture
that contained 100 mM sodium phosphate, pH 7.0, 20 
 
m
 
M
NADP
 
1
 
, 100 
 
m
 
M glucose-6-phosphate, 1 U of glucose-6-phos-
phate dehydrogenase, and a diluted amount of enzyme in a final
volume of 100 
 
m
 
l was used. The reaction was started by the ad-
dition of 1 
 
m
 
l of 500 
 
m
 
M 1-[
 
14
 
C]PGH
 
2
 
 (2.04 Gbq/mmol) and
was carried out at 37
 
8
 
C for 2 min and terminated by the addition
of 250 
 
m
 
l of a stop solution (30:4:1 vol/vol/vol diethyl ether/
methanol/2 M citric acid). To test for the nonenzymatic forma-
tion of PGF
 
2
 
a
 
, we incubated the reaction mixture containing all
of the components in the absence of the enzyme. The organic
phase (50 
 
m
 
l) was applied to 20 
 
3
 
 20-cm silica gel plates (Merck)
at 4
 
8
 
C, and the plates were developed with a solvent system of
90:2:1 vol/vol/vol diethyl ether/methanol/acetic acid at 
 
2
 
20
 
8
 
C.
The radioactivity on the plates was monitored and analyzed by a
Fluorescent Imaging Analyzer FLA 2000 and Mac Bas V2.5 soft-
ware (Fuji Photo Film Co.). For assessment of substrate specific-
ity, the reaction mixtures consisted of 100 mM sodium phos-
phate, pH 7.0, the purified recombinant enzyme, 100 
 
m
 
M
NADPH, and substrates at various concentrations, as indicated in
Table II, in a total volume of 500 
 
m
 
l. Reactions were initiated by
the addition of substrate, and the decrease in absorbance at 340
nm was monitored at 37
 
8
 
C. Blanks without enzyme or without
substrate were included. The 9,10-phenanthrenequinone reduc-
tase activity was chosen to represent 100% activity. For 1-[
 
14
 
C]-
PGD
 
2
 
 and PGE
 
2
 
 production, 40 
 
m
 
M 1-[
 
14
 
C]PGH
 
2
 
 was incu-
bated with either 250 
 
m
 
g of recombinant hematopoietic PGDS
Figure 1. Biosynthetic path-
ways of PGs from AA. 
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(22) or 500 
 
m
 
g of recombinant PGES (23). After incubation at
25
 
8
 
C for 5 min, the resulting PGs were extracted three times
with cold ethyl acetate, dried at a low temperature under vac-
uum, and used as substrates for the 
 
T. brucei
 
 PGF
 
2
 
a
 
 synthase (Tb-
PGFS) specificity study.
 
Extraction and Quantification of PGs.
 
After addition of
[
 
3
 
H]PGD
 
2
 
, [
 
3
 
H]PGE
 
2
 
, and [
 
3
 
H]PGF
 
2
 
a (60 Bq each per assay;
NEN Life Science Products), used as tracers to determine the re-
covery during extractions, PGs recovered from the trypanosome
culture medium (10 ml) and those from incubation of parasite ly-
sates (300 ml) were extracted and separated by HPLC as described
previously (9, 21). The resulting PGD2, PGE2, and PGF2a were
quantified by enzyme immunoassay (EIA) with their respective
EIA kits (Cayman Chemical).
Gas Chromatography–Mass Spectrometry Analysis. Gas chroma-
tography–selected ion monitoring (GC-SIM) analyses were run
on a Hitachi M-80B double-focusing mass spectrometer equipped
with a Van den Berg’s solventless injector and a fused silica capil-
lary column (Ultra no. 1; 25 m length, 0.32 mm internal diame-
ter, 2808C column temperature). PGs recovered from culture
media and those formed by the incubation of parasite lysates with
AA were fractionated by HPLC and converted into their corre-
sponding methyl ester (ME)-dimethylisopropylsilyl (DMiPS)
ether or ME-methoxime (MO)-DMiPS ether derivatives accord-
ing to the method described previously (24).
Purification and Determination of the Partial Amino Acid Sequences
of TbPGFS. Bloodstream-form T. brucei cells (5 3 1011) were
isolated from infected rats and lysed by hypotonic lysis. Soluble
proteins, obtained by differential centrifugation at 3,000 g for 15
min and then at 100,000 g for 1 h at 48C, were fractionated with
ammonium sulfate. The active fraction (40–100% saturation), re-
suspended in 0.1 M sodium phosphate, pH 7.0, was loaded onto
a Hiload 16/60 Superdex 75 pg gel filtration column (Amersham
Pharmacia Biotech) and eluted with 20 mM NaCl in 20 mM
Tris/Cl, pH 8.0. Active fractions were pooled, dialyzed against
20 mM sodium phosphate, pH 7.0, and concentrated by use of
Centricon centrifugal filters with a molecular mass cut-off of
3,000 daltons (Millipore). The concentrated active fraction was
further loaded onto a Resource PHE Hydrophobic interaction
column (Amersham Pharmacia Biotech), which had been equili-
brated with 2 M ammonium sulfate in 20 mM sodium phos-
phate, pH 7.0, and eluted with a decreasing linear gradient of
2–0 M ammonium sulfate in the same buffer containing 1% (vol/
vol) Tween 20. The active peak was dialyzed against 20 mM
Tris/Cl, pH 8.0, and applied to a Mono Q HR 10/10 ion ex-
change column (Amersham Pharmacia Biotech) equilibrated
with the same buffer. The elution was carried out with an in-
creasing linear gradient of 0–400 mM NaCl in the same buffer.
The active fraction was further purified by gel filtration on a
Hiload 16/60 Superdex 200 pg column (Amersham Pharmacia
Biotech).
Protein concentration was determined by use of bicinchoninic
acid reagent (Pierce Chemical Co.) with BSA as a standard fol-
lowing the manufacturer’s protocol. The purity of the protein
was assessed by SDS-PAGE on 14% (wt/vol) gels, and the gels
were stained with silver (Daiichi Pure Chemicals), sypro orange
(Bio-Rad Laboratories), or Coomassie Brilliant Blue (Daiichi
Pure Chemicals). Pure protein (220 mg) was subjected to in-gel
digestion with lysyl-endopeptidase for the determination of the
internal amino acid sequences according to Rosenfeld et al. (25).
PCR Amplification, cDNA Cloning, and Sequencing. Total
RNA was extracted from bloodstream-form T. brucei cells (4 3
108) by sour phenol, pH 4.5, saturated with TE buffer. First-
strand cDNA was synthesized by avian myeloblastosis virus re-
verse transcriptase after annealing 1 mg of T. brucei total RNA
with Oligo dT- Adaptor Primer (Takara Shuzo). For 39 rapid
amplification of cDNA ends (RACE), the first PCR amplifica-
tion was carried out with gene-specific primers, i.e., sense primer
59-AAGTTTATCGACACATGGAAGGCG-39 and antisense
primer M13 M4 (59-GTTTTCCCAGTCACGAC-39) and the
first-strand cDNAs as the template by the following program: af-
ter initial denaturation at 958C for 5 min, the PCR reaction pro-
ceeded at 948C for 20 s, 558C for 20 s, and 748C for 30 s for 30
cycles. PCR products from the first PCR amplification were
used as the templates for nested PCR amplification with other
gene-specific primers, i.e., sense primer 59-CTGTACGC-
CGATAAGAAGGTGCGCGCC-39 and antisense primer M13
M4. For 59 RACE, the resulting PCR product was amplified
with a 23-mer sense primer from T. brucei spliced leader se-
quence, 59-CGCTATTATTAGAACAGTTTCTG-39 (26) and
a gene-specific antisense primer, 59-GTGTTACTACTCGAA-
CACCGCA-39. The amplified fragments were cloned into
pGEM-T Easy vector (Promega). DNA sequences were deter-
mined from both strands with a SequiTherm cycle sequencing kit
(Epicentre Technologies) and a LI-COR automated DNA se-
quencer (model 4000; LI-COR Inc.).
Alignment of Primary Structures and Phylogenetic Analysis. The
sequences of 17 members of the aldo-keto reductase (AKR) su-
perfamily were retrieved from public databases. The amino acid
sequences were aligned with the TbPGFS sequence by using the
CLUSTAL W program (27). A neighbor-joining method (28) of
protein phylogeny was used to infer phylogenetic relationships
among the sequences.
Expression and Purification of the Recombinant Enzyme. The
coding region of TbPGFS cDNA was amplified by PCR using
sense primer 59-CGGAATTCATGGCTCTCACTCAATCCC-
TAA-39 and antisense primer 59-CGGTCGACCAGTGTTAC-
TACTCGAACACCG-39, which carried EcoRI and SalI restric-
tion sites at their respective 59 ends. The amplified fragments
containing the entire open reading frame were digested with
EcoRI and SalI and then cloned into the corresponding sites of
pMAL-c2 vector (New England Biolabs, Inc.). The resultant ex-
pression vector was used for transformation of Escherichia coli
DH5a. Transformed cells were cultured for 6–7 h in the pres-
ence of 0.5–1 mM isopropyl-b-d-thiogalactopyranoside (IPTG)
and then harvested and sonicated. The recombinant protein in
the soluble fraction was purified according to the manufacturer’s
protocol (New England Biolabs, Inc.).
Northern Blot Analysis. Total RNA from 107 cells of each
growth stage was isolated as described above, separated on 1.2%
(wt/vol) agarose–2% formaldehyde gels, and blotted onto a Hy-
bond N1 membrane (Amersham Pharmacia Biotech). RNA was
crosslinked by UV radiation for 6 min, and the membrane was
then dried for 2 h at 808C. After prehybridization, hybridization
was performed for 3 h in 53 SSPE (saline sodium phosphate
EDTA), 53 Denhardt’s solution, 0.5% (wt/vol) SDS, and 0.5 mg
sonicated salmon sperm DNA using the DIG system (Roche Di-
agnostics) according to the manufacturer’s protocol. After high-
stringency washing, the blot was pretreated with 0.1 M maleic
acid, 0.15 M NaCl, pH 7.5, containing 1% blocking reagent be-
fore the antidigoxigenin–AP Fab fragment was added and was
then developed with CDP-Star (all reagents from Roche Diag-
nostics). Chemiluminescence was detected by use of BioMax
Light-1 film (Sigma-Aldrich).1330 A Protozoan Prostaglandin F2a Synthase
Results and Discussion
Production and Secretion of PGD2, PGE2, and PGF2a from
AA by T. brucei. To assess possible PG production and se-
cretion by live trypanosomes, we cultured T. brucei in vitro
in a chemically defined medium supplemented with 10%
FCS. PGD2, PGE2, and PGF2a secreted into the culture
medium were quantified by EIA. As shown in Fig. 2 A, live
trypanosomes secreted small amounts of PGs: 75 6 10 pg/
ml for PGD2, 100 6 9.4 pg/ml for PGE2, and 156 6 20
pg/ml for PGF2a (n = 3). As with other parasitic protozoa,
T. brucei does not synthesize AA de novo from acetate (29),
but it does take up this fatty acid from its environment and
does incorporate it into its total and separate classes of lipids
(30, 31). The presence of phospholipase A2 (32, 33), an en-
zyme that catalyzes the release of AA from phospholipids,
in T. brucei indicates the existence of a free intracellular AA
source in this parasitic protozoan. Thus, the small amounts
of PGs, secreted by T. brucei in the absence of exogenously
added AA, were most likely produced from the intracellular
AA and from the trace amount of AA present in the serum
used for the medium preparation. We then grew trypano-
somes in the presence of 66 mM AA exogenously added
and which had no effect on cell growth (our unpublished
observations). PG accumulation in the media increased to
875 6 16 pg/ml for PGD2, 447 6 11 pg/ml for PGE2, and
Figure 2. PG production by T. brucei and mass spectra of trypanosomal PGs. (A) The PGs secreted into the culture media by live trypanosomes when
the organisms were cultured with or without AA were quantified. 2 AA and 1 AA indicate growth in the absence and presence of 66 mM AA, respec-
tively. PG detection limits were ,25, 11, and 10 pg/assay for PGD2, PGE2, and PGF2a, respectively. The values shown are the means from three inde-
pendent experiments along with SE. (B) PG production by T. brucei lysates. PGs were produced during the incubation of 1 mM AA with lysates of
bloodstream-form trypanosomes. The values shown are the means from three independent experiments along with SE. (C–E) To identify and quantify
the prostanoids by GC-MS, PGs from the incubation of trypanosome lysates with AA were extracted and resolved into PGD2, PGE2, and PGF2a as de-
scribed in Materials and Methods. After treatment (see Materials and Methods), the prostanoids were subjected to GC-MS. (C) Selected ion recordings
monitoring characteristic ions for PGD2 at m/z 595. (D) Those for PGE2 at m/z 595. (E) Those for PGF2a at m/z 668. The number indicates the ion in-
tensity for each peak. Upper mass spectra indicate traces of the selected ion recordings of the ME-MO-DMiPS ether derivatives of authentic PGD2 (C),
PGE2 (D), and PGF2a (E); and lower ones, traces of the selected ion recordings of the ME-MO-DMiPS ether derivatives of PGD2 (C), PGE2 (D), and
PGF2a (E) produced by trypanosome lysates. (F) Effects of heat treatment and of NSAIDs on PG production by trypanosome lysates. Nonboiled (control)
and boiled T. brucei lysates were incubated with 1 mM AA at 378C for 30 min in the absence of NSAIDs, and PGs produced were measured by EIA. To
investigate the effects of NSAIDs, we incubated nonboiled T. brucei lysates with 1 mM AA in the absence (control) or presence of the indicated concen-
trations of aspirin or indomethacin. The values shown are the means from three independent experiments along with SE.1331 Kubata et al.
211 6 6 pg/ml for PGF2a (n = 3), suggesting that, in vivo,
T. brucei would rely on AA uptake from its environment
(host tissues) to release significant amounts of PGs.
When the cell lysates were prepared from T. brucei
grown in vitro in the presence or absence of AA and incu-
bated with 1 mM AA, PGs were actively produced in a
time- and dose-dependent manner (data not shown).
PGF2a was the major prostanoid synthesized in both cases,
followed by PGE2 and PGD2 (Fig. 2 B). The addition of
AA during the cultivation of trypanosomes increased PG
formation by the lysates z12-fold for PGD2, 11-fold for
PGE2, and 5-fold for PGF2a.
The molecular masses and the characteristic fragment
ions of PGs produced by trypanosomes were determined
by GC-SIM analysis of the DMiPS ether derivatives. All of
the materials eluted from HPLC had exactly the expected
molecular masses: m/z 595 for PGD2 (Fig. 2 C) and PGE2
(Fig. 2 D) and m/z 668 for PGF2a (Fig. 2 E). Relative ion
intensity ratios of individual characteristic fragments of PG
derivatives in the eluates were identical to those of authen-
tic standards. Quantification by gas chromatography–mass
spectrometry analysis (GC-MS) of PGs extracted from cul-
ture medium or trypanosome lysates incubated with AA
gave values of the same order of magnitude as those deter-
mined by EIA, and finally PGs derived from trypanosomes
coeluted with authentic standards on HPLC and showed
the same titration curves as authentic PGs by EIA (data not
shown).
To determine the nature of the protozoan catalyst and to
evaluate whether or not the catalyst shares a kinship with
COX-1 and COX-2 from mammalian tissues, we investi-
gated the effects of heat and nonsteroidal antiinflammatory
drugs (NSAIDs) on PG production by T. brucei lysates.
Heating the lysates for 5 min at 1008C before incubation
with 1 mM AA reduced the levels of PGD2, PGE2, and
PGF2a synthesis to ,10% as compared with control values,
whereas the addition of 3 mM aspirin or 42 mM in-
domethacin to the reaction mixture had no inhibitory ef-
fects on PG formation (Fig. 2 F). The results reported here
show that PG-producing activities in T. brucei were heat
sensitive and unaffected by aspirin or indomethacin. As
NSAIDs are well established inhibitors of mammalian
COX-1 and COX-2 (34), the trypanosomal enzyme sys-
tem involved in PG synthesis from AA is markedly differ-
ent from its mammalian counterpart. Future investigations
in our laboratory will probably unravel the identity of the
enzymes involved in PG formation in this organism.
Enzymatic Formation of PGD2 and PGF2a from PGH2 by
T. brucei Lysates. Another approach to demonstrate de
novo synthesis of PGs in T. brucei was to use 1-[14C]PGH2
as a substrate. As an initial attempt to identify PG-produc-
ing enzymes in T. brucei, we prepared membrane and cyto-
solic fractions from bloodstream-form trypanosomes grown
in rats and incubated them with 1-[14C]PGH2 in the pres-
ence or absence of various cofactors. Two major PG syn-
thase activities were identified (Fig. 3, A and B). Mem-
brane proteins isomerized PGH2 to PGD2 (Fig. 3 A, lane
2). No PGD2 was formed during incubation of PGH2 with
heat-inactivated membrane fractions (data not shown) or in
the absence of membrane proteins, though a small nonen-
zymatic production of PGE2 was observed under the same
conditions (Fig. 3 A, lane 1).
On the other hand, in the presence of a NADPH-gener-
ating system, cytosolic proteins (Fig. 3 B, lane 2), but not
heat-inactivated ones (Fig. 3 B, lane 3), synthesized PGF2a
from PGH2. PGH2 was converted nonenzymatically to
PGE2 but not to PGF2a (Fig. 3 B, lane 1). Also, no PGF2a
formation was observed in the absence of the NADPH-
generating system or in the presence of 5 mM of other co-
factors such as dithiothreitol and glutathione (data not
shown). The profile of PG production from PGH2 is con-
sistent with that of PG synthesis from AA. Our data show
that PGH2 may be used as a substrate for PG synthesis by a
protozoan parasite. Earlier studies on cell–cell interactions
in the eicosanoid pathway have demonstrated the enzy-
matic cooperation between cell types (35). It has been
shown that platelets can transfer PGH2 to cultured endo-
thelial cells (36) and vascular tissue (37) for efficient con-
version to PGI2 and thromboxane, respectively, and that
platelets can utilize AA released by endothelial cells for li-
poxygenase metabolism (36). Additional evidence has also
shown that such an exchange may occur in vivo (38, 39).
However, it is not yet clear whether T. brucei utilizes PGH2
as a predominant pathway for PGF2a generation in host tis-
sues, because the nature of the trypanosomal catalyst that
converts AA to PGs is not known. The results presented
here show also that PGD2 and PGF2a synthases from PGH2
are catalyzed by trypanosomal enzymes. PGH D-isomerase
(PGD synthase) activity is localized in the membrane pro-
teins, a fact that made its purification difficult, and PGH
F2a reductase (PGF2a synthase) activity is in soluble pro-
Figure 3. De novo synthesis of PGD2 and PGF2a from PGH2 by T.
brucei lysates. Membrane or cytosolic fractions from long slender blood-
stream-form parasites (250 mg protein) were incubated with 5 mM 1-[14C]
PGH2 at 378C for 2 min. Arrows indicate the positions of PGH2, PGD2,
PGE2, and PGF2a. (A) T. brucei PGD synthase activity. Lane 1, control re-
action without membrane fraction; lane 2, reaction with membrane frac-
tion. (B) TbPGFS synthase activity was assayed as described in Materials
and Methods. Lane 1, control; lane 2, addition of cytosolic proteins; lane
3, addition of heat-treated cytosolic proteins. (C) SDS-PAGE of purified
TbPGFS. 5 mg of protein was subjected to electrophoresis on a 14%
SDS–polyacrylamide gel, and the protein bands were detected by silver
staining. Lane 1, molecular mass marker proteins; lane 2, purified active
fraction from Hiload 16/60 Superdex 200 pg.1332 A Protozoan Prostaglandin F2a Synthase
teins. As PGF2a was the major prostanoid synthesized by
trypanosome lysates, we started with the cytosolic activity
to purify TbPGFS.
Purification and Partial Amino Acid Sequencing of TbPGFS.
We purified TbPGFS from the soluble fraction of early
logarithmic growth phase bloodstream trypanosomes by
ammonium sulfate (40–100% saturation) fractionation and
sequential column chromatographies. TbPGFS activity was
monitored by the reduction of PGH2 in the presence of a
NADPH-generating system. Table I summarizes the results
of a typical purification procedure. Active fractions from
the final gel filtration (Hiload 16/60 Superdex 200 pg)
Table I. Purification of TbPGFS
Fraction Protein Total activity Specific activity Purification Recovery
mg nmol/min nmol/min/mg fold %
Cytosol 512 410 0.80 1 100
40–100% (NH4)2SO4 42 392 9.30 12 96
Superdex 75 15 328 22 28 80
Resource PHE 4.9 255 52 65 62
Mono Q 0.2 93 465 581 23
Superdex 200 0.06 52 860 1,075 13
Figure 4. Sequence homology of TbPGFS with members of the AKR
superfamily. (A) Multiple sequence alignment of deduced TbPGFS amino
acid sequence with representative members of the AKR superfamily. The
amino acid sequences were taken from the sequence databases SwissProt
(SP), Protein Identification Resource (PIR), and GenBank (GB). TbPGF
synthase is aligned with: L major-putRed, L. major putative reductase (SP
P22045) (57); BovPGFS, bovine lung PGFS (GB J03570) (58); Bsub-put-
Mordh, B. subtilis putative morphine dehydrogenase (GB AF008220) (59);
Pstipitis-XR, Pichia stipitis xylose reductase (SP P31867) (60); and Soy-
ChalRed, soybean chalcone reductase (SP P26690) (61). Dashes show the
gap used to maximize the similarity. Conserved residues with TbPGF syn-
thase are highlighted in red. Underlined black bold letters indicate the pep-
tide sequences identified from purified native TbPGFS and used for primer
design. (B) Neighbor-joining tree of TbPGFS and some members of the
AKR superfamily. Amino acid sequences of oxidoreductases from pig, cow, human, mouse, L. major, apple, soybean, yeast, and bacteria were selected as
representatives for mammals, protozoa, plants, and prokaryotes to simplify the phylogenetic analysis. Numbers at the nodes represent bootstrap propor-
tions based on 1,000 replicates. Por-ALR, porcine aldose reductase (SP P80276); Bov-ADR, bovine aldehyde reductase (SP P16116); Hum-3a-HSDdh,
human 3a-hydroxysteroid dehydrogenase (GB NM003739); Mou-17b-HSDdh, mouse estradiol 17b-(hydroxysteroid) dehydrogenase (PIR A56424);
App-S6Pdh, apple NADP-dependent sorbitol-6-phosphate dehydrogenase (SP P28475); Spombe-OxidoRed, Schizosaccharomyces pombe probable oxi-
doreductase (SP Z99165); Cb-25dkg, Corynebacterium sp. 2,5-diketo-gulonate reductase (SP P15339); Ecoli-OxidoRed, E. coli hypothetical oxidoreduc-
tase (SP Q46857); Mtub-Rv2971, Mycobacterium tuberculosis hypothetical protein Rv2971 (GB Z83018); Strepm-putRed, Streptomyces coelicolor putative
oxidoreductase (GB AL034443); Ps put-Mordh, Pseudomonas putida morphine dehydrogenase (GB M94775); and Therm-OxidoRed, Thermotoga maritima
oxidoreductase (GB AE001762).1333 Kubata et al.
were pooled and analyzed by SDS-PAGE. Upon silver
staining, a single band with a molecular mass of 33 kD was
detected (Fig. 3 C, lane 2). Finally, TbPGFS was purified
1,075-fold with a recovery of z13% and a specific activity
of 860 nmol/min/mg of protein.
We subjected the purified protein to partial amino acid
sequencing. Although the NH2 terminus was blocked, we
identified two amino acid sequences, LWNSDQGYES and
NIAVTAWSPL (Fig. 4 A), of two internal peptide frag-
ments from in-gel digestion of the purified TbPGFS with
lysyl-endopeptidase.
Cloning of TbPGFS cDNA. From a database search us-
ing the two amino acid sequences mentioned above, we
identified the corresponding 538-bp gene fragment in pub-
lic databases (available from EMBL/GenBank/DDBJ under
accession number AQ945329) that encoded the amino acid
sequence NIAVTAWSPL. As this genomic clone was
truncated at the NH2 terminus, we isolated a 1,164-bp full-
length cDNA for TbPGFS by the RACE technique with
Oligo dT- Adaptor Primer, T. brucei–specific spliced leader,
and gene-specific primers. The cDNA encoded an open
reading frame of 828 bp, which predicted a protein com-
posed of 276 amino acid residues (Fig. 4 A) with a calcu-
lated molecular mass of 30,991 daltons. The deduced
amino acid sequence of the cDNA contained both peptide
sequences, LWNSDQGYES and NIAVTAWSPL, as iden-
tified in the isolated protein.
Relationship of the TbPGFS to Other Members of the AKR
Superfamily. Sequence analysis, database search, and align-
ment of the TbPGFS amino acid sequence (Fig. 4 A) re-
vealed that the TbPGFS is a member of subfamily 5A of
the AKR superfamily (40). The TbPGFS amino acid se-
quence showed 61% identity to that of a Leishmania major
putative reductase and between 48 and 55% identity to
bacterial protein sequences. In contrast, TbPGFS showed
rather low identities to AKR from mammals and plants
(39–40%). Furthermore, phylogenetic analysis (Fig. 4 B)
confirmed that TbPGFS formed a clade together with L.
major putative reductase and Bacillus subtilis putative mor-
phine dehydrogenase. However, bootstrap proportions of
the clades forming Trypanosomatid-Bacillus and Leishma-
nia-Trypanosoma were relatively low (500–600), and thus
the statistical support for any particular topology linking
TbPGFS to a mammal, plant, yeast, or bacteria AKR clus-
ter was rather weak. These results demonstrate that Tb-
PGFS is different not only from other AKRs of mammals,
including mammalian PGFS, but from AKRs of plants,
yeast, and prokaryotes, indicating that it is a novel enzyme.
The fact that this enzyme forms a distinct and distant clade
from mammalian PGF synthases demonstrates that the pro-
cess of PG formation existed early in the evolution of the
animal kingdom.
Expression and Characterization of Recombinant TbPGFS
Protein. TbPGFS protein was heterologously expressed in
a pMAL-c2 expression system. The recombinant enzyme
was produced as a fusion protein with maltose-binding
protein (MBP) in the cytosolic fraction of E. coli after
IPTG induction (Fig. 5 A, lane 3). Upon SDS-PAGE, the
fusion protein, MBP–TbPGFS, exhibited a molecular mass
of z76 kD (Fig. 5 A, lane 3). Crude proteins from E. coli
expressing MBP–TbPGFS (Fig. 5 B, lane 4), but not lysates
from E. coli host or from E. coli transformed with empty
pMAL-c2 vector (Fig. 5 B, lanes 2 and 3), converted PGH2
to PGF2a only in the presence of a NADPH-generating
system, indicating that the detected synthase activity de-
pended on T. brucei protein and not on any contaminating
activity from the host or from the vector. This is in good
agreement with early results demonstrating de novo syn-
thesis of PGF2a from PGH2 by the isolated enzyme (Figs. 3
Figure 5. Expression of TbPGFS in E. coli and TbPGFS activity of the
recombinant protein. (A) TbPGFS was expressed as a fusion protein with
MBP in E. coli and purified as described in Materials and Methods. Lane
1, noninduced lysate of E. coli DH5a; lane 2, IPTG-induced lysate of E.
coli DH5a transformed with empty pMAL-c2 vector after 4-h induction;
lane 3, IPTG-induced lysate of E. coli DH5a transformed with pMAL-
c2-TbPGFS after 4 h; lane 4, purified MBP–TbPGFS fusion protein; lane
5, enzyme after purification by gel filtration on Superdex 75, after cleav-
age with factor Xa to separate TbPGFS from MBP; lane 6, purified Tb-
PGF synthase after Mono S column chromatography; lane 7, molecular
mass marker proteins. (B) Reduction of PGH2 by recombinant TbPGFS.
Lane 1, substrate incubated in the absence of enzyme; lane 2, substrate in-
cubated with 100 mg total protein from lysate of the host E. coli DH5a;
lane 3, substrate incubated with 100 mg protein from lysate of induced E.
coli cells containing empty pMAL-c2 vector; lane 4, incubation with 25
mg of lysate from induced E. coli that contained pMAL-c2-TbPGFS. (C)
Effect of phenanthrenequinone on TbPGFS activity. The enzymatic ac-
tivity was determined as described in Materials and Methods. 1-[14C]
PGH2 (5 mM) was incubated in the presence of 40 mM of phenanthrene-
quinone without (lane 1) or with 14 mg of purified TbPGFS (lane 2). (D)
Lack of reduction of PGD2 and PGE2 by purified TbPGFS. 1-[14C]PGD2
and 1-[14C]PGE2 (10 mM), produced as described in Materials and Meth-
ods, were incubated without (lanes 1 and 3) or with (lanes 2 and 4) 14 mg
of purified TbPGFS.1334 A Protozoan Prostaglandin F2a Synthase
B and 5 B), and these findings show that the cloned T. bru-
cei cDNA encoded a bona fide PGF synthase and provide
conclusive evidence for the existence of specific PG bio-
synthetic pathways in a pathogenic parasite. The fusion
protein was purified by amylose affinity chromatography
(Fig. 5 A, lane 4), gel filtration after factor Xa cleavage to
separate TbPGFS from MBP (Fig. 5 A, lane 5), and ion ex-
change chromatography (Fig. 5 A, lane 6). The purified re-
combinant TbPGFS had an apparent molecular mass of 33
kD (Fig. 5 A, lane 6), identical to that of the wild-type pro-
tein (Fig. 3 C, lane 2).
Characterizing the purified recombinant enzyme and
comparing its molecular properties with those of a number
of mammalian PGF synthases purified and characterized
from our laboratory (41–45), we found that TbPGFS ex-
hibited a high and specific PGFS activity toward PGH2 (2
mmol/min/mg), a broad range of temperatures (25–408C),
and pH (6–9) optima, the lowest Km (1.3 mM) for PGH2,
and the highest kcat value of 63 min21 (Table II). As a
member of the AKR superfamily, the purified TbPGFS
showed AKR activity toward other substrates as well. It ex-
hibited significantly high activity toward 9,10-phenan-
Table II. Substrate Specificity and Kinetic Parameters of TbPGFS
Substrate Concentration Relative activity Km Vmax
mM% mM mmol/min/mg
9,10-Phenanthrenequinone 40 100 0.42 48.0
p-Nitrobenzaldehyde 40 64 0.80 22.0
PGH2 5 44 1.30 2.0
Progesterone 40 2 ND ND
Sodium glucuronate 40 1 ND ND
Testosterone 40 0.4 ND ND
NADPH – – 5.7 1.5
NADH – – – nd
ND, not determined; nd, not detected.
Figure 6. PG production, dif-
ferential expression of TbPGFS
mRNA, and TbPGFS activity
during the T. brucei life cycle. (A)
PG secretion by bloodstream-
form live trypanosomes from
early logarithmic growth and late
stationary phases. (B) PG pro-
duction by lysates from blood-
stream-form trypanosomes from
early logarithmic and late station-
ary growth phases. (C) Northern
blot analysis. T. brucei total RNA
(3.9  mg) was isolated from the
bloodstream-form population
from infected rats (left panel) and
from early logarithmic (right
panel, 19 h) and late stationary
growth phase (right panel, 44 h)
cells of the cultured bloodstream-
form population. Total RNA
was hybridized with a probe de-
rived from the TbPGFS cDNA
coding region. (D) TbPGFS ac-
tivity of the lysates (50 mg pro-
tein) from early logarithmic and
late stationary growth phase try-
panosomes. Lysates of respective
cells were incubated with 5 mM
PGH2. The reaction products
were analyzed by thin-layer
chromatography as described in
the legend to Fig. 4 (n = 3).1335 Kubata et al.
threnequinone,  p-nitrobenzaldehyde (the common sub-
strates for this superfamily), and PGH2 but remarkably
weak activity toward progesterone, sodium glucuronate, or
testosterone (Table II). However, the AKR substrates did
not compete with PGH2 when added simultaneously in ex-
cess (Fig. 5 C), suggesting the existence of different cata-
lytic sites for both types of substrate.
PGF2a is synthesized either by the 9,11-endoperoxide
reduction of PGH2 or by the 9-keto reduction of PGE2
(Fig. 1; reference 46). These reactions are catalyzed by
PGH 9,11-endoperoxide reductase (41) and PGE2 9-keto
reductase (46, 47) in mammals. A third pathway, the 11-
keto reduction of PGD2 catalyzed by PGD 11-keto reduc-
tase, does not produce PGF2a as initially thought. Instead, it
leads to the formation of 9a,11b-PGF2, a stereoisomer of
PGF2a (48). PGFSs described to date are enzymes that ex-
hibit two activities on the same molecule, i.e., PGH 9,11-
endoperoxide reductase activity and PGD 11-keto reduc-
tase activity (41, 48). To elucidate the catalytic properties
of TbPGFS, we incubated the recombinant TbPGFS
with either 1-[14C]PGD2 (Fig. 5 D, lanes 1 and 2) or
1-[14C]PGE2 (Fig. 5 D, lanes 3 and 4). No 9a,11b-PGF2 or
PGF2a formation was observed with either substrate. This
finding demonstrates that TbPGFS is a rather specific PGH
9,11-endoperoxide reductase devoid of any PGD 11-keto
reductase or PGE 9-keto reductase activity on the same
molecule.
PG Production and Expression of TbPGFS mRNA during
T. brucei Cell Growth. In the protozoan parasites Trypano-
soma and Leishmania, several enzymes involved in citric acid
cycle (49), respiratory chain activities (50–54), lysosomal
function, or in the metabolism of protein, carbohydrate,
and purine are developmentally regulated. To investigate
PG production and the expression of TbPGFS mRNA
during the T. brucei life cycle, we cultured trypanosome
cells in the presence of 66 mM exogenous AA and har-
vested them at 19 h for early logarithmic phase or at 44 h
for late stationary phase. We then used EIA to quantify PGs
secreted by live trypanosomes into the media or produced
by trypanosome lysates. Trypanosome cells from both the
early logarithmic and late stationary phases released PGD2,
PGE2, and PGF2a (Fig. 6 A). No significant difference was
observed between the levels of PGD2 and PGE2 secreted
by the two growth stages. However, early logarithmic
phase trypanosomes released PGF2a fourfold more than
those in late stationary phase. On the other hand, lysates
from early logarithmic and late stationary phase trypano-
somes produced different levels of all three PGs (Fig. 6 B).
Early logarithmic phase trypanosomes produced a signifi-
cantly high level of PGF2a as compared with lysates from
late stationary phase organisms (Fig. 6 B).
Northern blot analysis revealed that TbPGFS mRNA
was abundantly expressed during the early logarithmic
phase of trypanosomes grown in rats (Fig. 6 C) or in vitro
(Fig. 6 C, 19 h) and was downregulated during the late sta-
tionary growth stage of these organisms (Fig. 6 C, 44 h).
The expression profile, shown in Fig. 6 C, was found to be
in good agreement with the TbPGFS activity in the re-
spective cells (Fig. 6 D), which was higher during the early
logarithmic growth stage of cells from rats (1.00 6 0.07
nmol/min/mg) and during the early logarithmic growth
stage of cells from in vitro culture (0.42 6 0.02 nmol/min/
mg) but lower during the late stationary growth stage of
these organisms (0.04 6 0.01 nmol/min/mg). Taken to-
gether, our data show that PG production as well as Tb-
PGFS activity and TbPGFS mRNA expression are devel-
opmentally regulated.
Infection of mammals by African trypanosomes results in
the release of high levels of PGs (16, 17) that may, in part,
be involved in the pathogenesis of the disease. It is gener-
ally believed and accepted that the PGs are produced by
host cells after their stimulation with trypanosome products
(55, 56). We have shown that the parasite itself produces
PGs and may contribute directly to the production of these
mediators in mammals. However, the physiological rele-
vance of PG production in T. brucei remains unknown.
The findings reported here open up ways to investigate the
role of TbPGFS in T. brucei replication and development as
well as provide a new tool to study the role of parasite-
derived PGs in the pathogenesis of African trypanosomiasis.
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